Toyoshima, Kuniyoshi http://orcid.org/0000-0002-5618-3657
Ichiki, Masahiko
Inoue, Takeshi
Shimura, Akiyoshi
Masuya, Jiro
Fujimura, Yota
Higashi, Shinji
Kusumi, Ichiro
Funding for this research was provided by:
SENSHIN Medical Research Foundation
Japanese Ministry of Education, Culture, Sports, Science and Technology (16K10194)
Research and Development Grants for Comprehensive Research for Persons with Disabilities from the Japan Agency for Medical Research and Development (JP18dk0307060)
JSPS KAKENHI (JP20K16662)
Article History
Received: 14 January 2021
Accepted: 7 March 2022
First Online: 22 March 2022
Declarations
:
: The Local Ethics Committee of Tokyo Medical University approved this study (approval number: SH3502), which was conducted in accordance with the Declaration of Helsinki [CitationRef removed]. All participants provided written informed consent before participating of the present study.
: Not applicable.
: Jiro Masuya has received personal compensation from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda Mental Health Foundation, as well as grants from Pfizer. Masahiko Ichiki received personal compensation from Otsuka Pharmaceutical, Pfizer, Eli Lilly, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Takeda Pharmaceutical, MSD, Dainippon Sumitomo Pharma, and Eisai; grants from Otsuka Pharmaceutical, Eli Lilly, Eisai, Shionogi, Takeda Pharmaceutical, MSD, and Pfizer; and is a member of the advisory board of Meiji Seika Pharma. Ichiro Kusumi has received honoraria from Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Janssen Pharmaceutical, Lundbeck, Meiji Seika Pharma, Mochida Pharmaceutical, MSD, Mylan, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Shire, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Tsumura, and Yoshitomiyakuhin, and has received research/grant support from Asahi Kasei Pharma, Astellas, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Mochida Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical and Tanabe Mitsubishi Pharma. Takeshi Inoue is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma and has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma. Yota Fujimura received research and grant support from Novartis Pharma, Otsuka Pharmaceutical, Astellas, Dainippon Sumitomo Pharma, and Shionogi. Shinji Higashi received honoraria from Dainippon Sumitomo Pharma and Novartis Pharma. Akiyoshi Shimura reports personal fees from Eisai, Sumitomo Dainippon Pharma, MSD, Yoshitomi Yakuhin Corporation, and Meiji Seika Pharma, outside the submitted work. Kuniyoshi Toyoshima does not have any actual or potential conflict of interest.